NCT00409565View on ClinicalTrials.gov

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Head and Neck CancerSquamous Cell Carcinoma
Interventions
DRUG

Cetuximab

"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"

DRUG

Bevacizumab

Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given

Trial Locations (4)

15232

UPMC / UPMC Cancer Centers, Pittsburgh

44106

Case Western Reserve University, Cleveland

77030

University of Texas MD Anderson, Houston

48109-0848

University of Michigan, Ann Arbor

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00409565 - A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter